Skip to content
Inciteful Med

Living with SFT: Surveillance and Survivorship

Last updated:

SFT requires lifelong surveillance because the tumor can recur 10 to 20 years after initial treatment. Patients follow a risk-adapted scan schedule, typically starting with frequent checks and moving to annual or biennial monitoring indefinitely to detect local recurrence or distant metastasis early.

Key Takeaways

  • • Solitary Fibrous Tumor (SFT) carries a risk of late recurrence even 10 to 20 years after treatment.
  • • Lifelong monitoring is recommended over a standard 5-year discharge to ensure early detection of recurrence.
  • • Surveillance schedules typically start with frequent scans every 3-6 months and transition to annual checks after 5 years.
  • • Doctors use the term 'No Evidence of Disease' (NED) rather than 'cured' to reflect the need for ongoing vigilance.
  • • Managing 'scanxiety' is a critical part of long-term survivorship and emotional well-being.

Completing treatment for a Solitary Fibrous Tumor (SFT) is a major milestone, but it also marks the beginning of a lifelong journey of monitoring. Because SFT is known for its unpredictable behavior, “survivorship” in this context means staying vigilant even when you feel perfectly healthy [1][2].

The Reality of Late Recurrence

One of the most unique aspects of SFT is the risk of late recurrence [3]. While many cancers are considered “cured” if they don’t return within five years, SFT can reappear 10, 15, or even 20 years after the original tumor was removed [3][4].

  • Local Recurrence: The tumor may grow back in the same spot where it first appeared [5].
  • Distant Metastasis: SFT can spread to distant parts of the body, such as the lungs, liver, or bones [3]. For brain and spine tumors, these distant spreads have been documented as late as 9 to 13 years after diagnosis [3].

Because of this long-term risk, doctors often prefer the term No Evidence of Disease (NED) over “cured” [1]. NED means that current scans show no signs of the tumor, but it acknowledges that lifelong monitoring is necessary to catch any potential changes early [6][7].

Your Surveillance Schedule

While there is no single “one-size-fits-all” schedule, your follow-up plan will be tailored to your specific risk category (low, intermediate, or high) and the location of your tumor [8][9].

A typical surveillance plan might include:

  • The First 2 Years: Frequent scans (every 3 to 6 months) using MRI or CT to monitor for early recurrence [10][11].
  • Years 3 to 5: Scans may move to every 6 to 12 months if everything remains stable [12].
  • Year 10 and Beyond: Unlike many other conditions, monitoring for SFT should continue indefinitely. Even after a decade of “clean” scans, annual or biennial check-ups are often recommended [3][4].

Managing ‘Scanxiety’

The stress of waiting for follow-up scans and results is so common it has its own name: Scanxiety [13][14]. This anxiety often peaks in the days leading up to the scan and during the waiting period for results [15].

To manage scanxiety, consider these evidence-based strategies:

  • Minimize the Wait: Ask your doctor how quickly results will be available. Knowing you’ll hear back by a specific time can reduce the “limbo” period [16][17].
  • Focus on the Present: Techniques that focus on the “here and now,” rather than worrying about future outcomes, have been shown to help reduce anticipatory distress [18][19].
  • Seek Support: Having a friend or family member accompany you to appointments, or connecting with other SFT survivors, can provide vital emotional buffering [20].
  • Information as Power: Understanding your specific risk and why the scans are necessary can help you feel more in control of your health journey [17].

Frequently Asked Questions

Why do I need scans 10 years after SFT treatment?
SFT has a unique risk of late recurrence, meaning tumors can return 10, 15, or even 20 years after removal. Because of this long-term risk, doctors recommend indefinite monitoring to catch any potential regrowth or spread as early as possible.
What is the difference between 'No Evidence of Disease' (NED) and being 'cured'?
Doctors prefer 'No Evidence of Disease' (NED) because it accurately reflects that current scans show no tumor, while acknowledging the possibility of future recurrence. The term 'cured' implies the tumor will never return, which cannot be guaranteed with SFT due to its unpredictable nature.
How often will I need follow-up scans?
While plans vary based on your specific risk level, a typical schedule involves scans every 3 to 6 months for the first two years. If stable, scans may occur every 6 to 12 months for years 3 to 5, followed by annual or biennial check-ups indefinitely.
What is scanxiety and how can I manage it?
Scanxiety refers to the stress and anxiety patients feel leading up to medical scans and while waiting for results. Strategies to manage it include asking for a clear timeline on results, bringing a support person to appointments, and focusing on present-moment coping techniques.
Where does SFT typically recur?
SFT can recur locally at the original tumor site or spread to distant areas like the lungs, liver, or bones. Symptoms depend on the location but may include new lumps, persistent pain, or neurological changes like headaches or weakness.

Questions for Your Doctor

  • • Based on my tumor's risk score or WHO grade, what is my specific imaging schedule for the next 2, 5, and 10 years?
  • • Since late recurrence is a known risk for SFT, how will our surveillance plan change after I hit the 5-year and 10-year milestones?
  • • Which imaging modality (MRI, CT, or PET/CT) is best for monitoring my specific tumor location and checking for distant spread?
  • • Can you explain why we use the term 'No Evidence of Disease' (NED) instead of 'cured' for my situation?
  • • How quickly can I expect to receive my scan results to help minimize my anxiety during the waiting period?

Questions for You

  • • Have you noticed any new lumps, persistent pain, or changes in your neurological function (like headaches or weakness) since your treatment?
  • • How do you typically feel in the days leading up to a follow-up scan, and what activities or support systems help you manage that stress?
  • • Do you have a system, like a calendar or health app, to keep track of your long-term follow-up appointments over the next decade?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Acute urinary retention due to solitary fibrous tumor of the abdominal wall.

    Fernández-Sanmillán D, De Melo Santos DM, Fernandez EL, Hernandez JRH

    Turkish journal of urology 2019; (45(6)):471-473 doi:10.5152/tud.2018.23255.

    PMID: 31603423
  2. 2

    Solitary Fibrous Tumor of the Right Elbow: A Case Report.

    Mach M, Ostrowski T, Maciejewski K, et al.

    Cureus 2025; (17(7)):e88175 doi:10.7759/cureus.88175.

    PMID: 40687408
  3. 3

    Central nervous system solitary fibrous tumors: Case series in accordance with the WHO 2021 reclassification. Framework for patient surveillance.

    Matthijs V, Beckers R, Broecke CV, et al.

    Acta neurochirurgica 2024; (166(1)):414 doi:10.1007/s00701-024-06304-7.

    PMID: 39417883
  4. 4

    Liver Metastasis From Intracranial Hemangiopericytoma 8 Years After Initial Resection: Case Report.

    Hendrickson Rahmlow T, Kolagatla S, Mattingly K, et al.

    Journal of investigative medicine high impact case reports 2022; (10()):23247096221132244 doi:10.1177/23247096221132244.

    PMID: 36281561
  5. 5

    Solitary Fibrous Tumors Arising from Bilateral Ovaries: A Case Report and Review of the Literature.

    Tian T, Ye J, Sun J

    Current medical imaging 2022; (18(8)):898-901 doi:10.2174/1573405617666211209120409.

    PMID: 34886778
  6. 6

    Adrenal solitary fibrous tumor: A case report.

    Yonli DS, Chakroun M, Mokadem S, et al.

    Urology case reports 2019; (27()):100919 doi:10.1016/j.eucr.2019.100919.

    PMID: 31687355
  7. 7

    Malignant solitary fibrous tumor of the orbit: Spectrum of histologic features.

    Ediriwickrema LS, Burnstine M, Saber MS, Rao N

    American journal of ophthalmology case reports 2017; (5()):7-10 doi:10.1016/j.ajoc.2016.10.007.

    PMID: 29503937
  8. 8

    Solitary fibrous tumor of the pineal region with delayed ectopic intracranial metastasis: A case report and review of the literature.

    Wang Y, Zhang J, Liu Q, et al.

    Medicine 2019; (98(21)):e15737 doi:10.1097/MD.0000000000015737.

    PMID: 31124953
  9. 9

    Hybrid video-assisted thoracoscopic resection of a massive mediastinal solitary fibrous tumor: overcoming challenges: a case report.

    Deeb S, Deeb N, Douden B, et al.

    Journal of medical case reports 2025; (19(1)):310 doi:10.1186/s13256-025-05377-x.

    PMID: 40611223
  10. 10

    Intracranial solitary fibrous tumor mimicking meningioma: A case report.

    Cheng L, Ni H, Dai Y

    Medicine 2020; (99(50)):e23504 doi:10.1097/MD.0000000000023504.

    PMID: 33327290
  11. 11

    Solitary Fibrous Tumor of Adrenal Gland and Review of the Literature.

    Ambardjieva M, Saidi S, Jovanovic R, et al.

    Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) 2021; (42(3)):63-69 doi:10.2478/prilozi-2021-0036.

    PMID: 35032374
  12. 12

    Clinical analysis of 47 cases of solitary fibrous tumor.

    Ge W, Yu DC, Chen G, Ding YT

    Oncology letters 2016; (12(4)):2475-2480 doi:10.3892/ol.2016.4967.

    PMID: 27698815
  13. 13

    Scanxiety and Fear of Recurrence in Young Adult Female Breast and Gynaecological Cancer Survivors: Investigating Shared Mechanisms.

    Patel DS, Webster SN, Dowling EJ, et al.

    Psycho-oncology 2024; (33(12)):e70050 doi:10.1002/pon.70050.

    PMID: 39694862
  14. 14

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  15. 15

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  16. 16

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  17. 17

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  18. 18

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  19. 19

    The relationships between symptoms and quality of life over the course of cognitive-behavioral therapy for panic disorder in Japan.

    Ogawa S, Kondo M, Okazaki J, et al.

    Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists 2017; (9(2)) doi:10.1111/appy.12249.

    PMID: 27481539
  20. 20

    Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

    Hussain M, Chau S, Turner M, Paterson C

    Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

    PMID: 37735038

This guide to SFT survivorship and surveillance is for educational purposes only. Always follow the specific follow-up schedule recommended by your oncology team to address your individual risk factors.

Stay up to date

Get notified when new research about Solitary Fibrous Tumor (SFT) is published.

No spam. Unsubscribe anytime.